Clinical Trial Search

Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) — 35.3; 13.8 Percentage of study group

Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 28; 30; 31; 14 Participants

Primary: The Percentage of Eligible Patients Who Agreed to Participate in the Study. — 40 Participants

Primary: Index of Microcirculatory Resistance — 21.94; 23.22; 32.95 IMR

Primary: Change in Left Ventricular End Systolic Volume Index — -4.0; -2.0 ml/m^2 — p=0.19

Primary: Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke) — 439; 472 Participants — p=0.121

Primary: Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h) — 6307; 9791 ng*h/mL

Primary: Global Infarct Size — 5.453; 8.598; 9.004; 7.819 Percentage of global infarct size

Primary: Postinfarct Remodeling — 11; 6 Number of participants with remodeling

Primary: Platelet Reactivity Measured by VerifyNow PRU — 63; 214 P2Y12 reaction units (PRU) — p=<0.001

Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L

Primary: P2Y12 Reaction Units (PRU) — 95; 164 PRU — p=0.022

Primary: All Cause Mortality and Readmission at 30 Days. — 16; 28 participants — p=<0.05

Primary: Final Infarct Size — 5; 6 % of LV